Similarly, IL-6 can enhance B cell activity by increasing the production of anti-dsDNA in SLE patients while treatment with anti-IL-6 to ameliorate the SLE activity also reduces B cell proliferation induced by anti-CD40 and decreases the frequency of MZ-B cells (Liang et al., 2006). The gene discussed is CD40; the disease is systemic lupus erythematosus.